secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001753926-24-001275
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell raises $750k via convertible note and secures $30M committed equity facility
--------------------------------------------------------------------------------

- $750k convertible note issued, 6% interest (12% default), convertible at $1.506/share, floor $0.231, maturity Aug 24, 2025.
- Committed equity facility with Tikkun Capital for up to $30M; shares sold at 90% of VWAP over up to 24 months.
- $750k commitment fee paid to Tikkun; $75k legal fees reimbursed; restrictions on variable rate transactions.
- Stockholder approval required to exceed exchange cap; meeting within 90 days for note; similar cap for equity facility.
- Proceeds to fund clinical work on CC8464 and CT2000 compounds and for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001275/0001753926-24-001275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001275/g084348_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer